Skip to main content
Erschienen in: International Journal of Hematology 1/2015

01.07.2015 | Case Report

SVA retrotransposition in exon 6 of the coagulation factor IX gene causing severe hemophilia B

verfasst von: Yuki Nakamura, Moe Murata, Yuki Takagi, Toshihiro Kozuka, Yukiko Nakata, Ryo Hasebe, Akira Takagi, Jun-ichi Kitazawa, Midori Shima, Tetsuhito Kojima

Erschienen in: International Journal of Hematology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Hemophilia B is an X-linked recessive bleeding disorder caused by abnormalities of the coagulation factor IX gene (F9). Insertion mutations in F9 ranging from a few to more than 100 base pairs account for only a few percent of all hemophilia B cases. We investigated F9 to elucidate genetic abnormalities causing severe hemophilia B in a Japanese subject. We performed PCR-mediated analysis of F9 and identified a large insertion in exon 6. Next, we carried out direct sequencing of a PCR clone of the whole insert using nested deletion by exonuclease III and S1 nuclease. We identified an approximately 2.5-kb SINE-VNTR-Alu (SVA)-F element flanked by 15-bp duplications in the antisense orientation in exon 6. Additionally, we carried out exontrap analysis to assess the effect of this retrotransposition on mRNA splicing. We observed that regular splicing at exons 5 and 6 of F9 was disturbed by the SVA retrotransposition, suggesting that abnormal FIX mRNA may be reduced by nonsense-mediated mRNA decay. In conclusion, this is the first report of SVA retrotransposition causing severe hemophilia B; only five cases of LINE-1 or Alu retrotranspositions in F9 have been reported previously.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985;24:3736–50.PubMedCrossRef Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985;24:3736–50.PubMedCrossRef
3.
Zurück zum Zitat Li T, Miller CH, Payne AB, Craig Hooper W. The CDC hemophilia B mutation project mutation list: a new online resource. Mol Genet Genomic Med. 2013;1:238–45.PubMedCentralPubMedCrossRef Li T, Miller CH, Payne AB, Craig Hooper W. The CDC hemophilia B mutation project mutation list: a new online resource. Mol Genet Genomic Med. 2013;1:238–45.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Kojima T, Tanimoto M, Kamiya T, Obata Y, Takahashi T, Ohno R, et al. Possible absence of common polymorphisms in coagulation factor IX gene in Japanese subjects. Blood. 1987;69:349–52.PubMed Kojima T, Tanimoto M, Kamiya T, Obata Y, Takahashi T, Ohno R, et al. Possible absence of common polymorphisms in coagulation factor IX gene in Japanese subjects. Blood. 1987;69:349–52.PubMed
5.
Zurück zum Zitat Okumura K, Fujimori Y, Takagi A, Murate T, Ozeki M, Yamamoto K, et al. Skewed X chromosome inactivation in fraternal female twins results in moderately severe and mild haemophilia B. Haemophilia. 2008;14:1088–93.PubMedCrossRef Okumura K, Fujimori Y, Takagi A, Murate T, Ozeki M, Yamamoto K, et al. Skewed X chromosome inactivation in fraternal female twins results in moderately severe and mild haemophilia B. Haemophilia. 2008;14:1088–93.PubMedCrossRef
6.
Zurück zum Zitat Kato I, Takagi Y, Ando Y, Nakamura Y, Murata M, Takagi A, et al. A complex genomic abnormality found in a patient with antithrombin deficiency and autoimmune disease-like symptoms. Int J Hematol. 2014;100:200–5.PubMedCrossRef Kato I, Takagi Y, Ando Y, Nakamura Y, Murata M, Takagi A, et al. A complex genomic abnormality found in a patient with antithrombin deficiency and autoimmune disease-like symptoms. Int J Hematol. 2014;100:200–5.PubMedCrossRef
7.
Zurück zum Zitat Takagi A, Kojima T, Tsuzuki S, Katsumi A, Yamazaki T, Sugiura I, et al. Structural organization and promoter activity of the human ryudocan gene. J Biochem. 1996;119:979–84.PubMedCrossRef Takagi A, Kojima T, Tsuzuki S, Katsumi A, Yamazaki T, Sugiura I, et al. Structural organization and promoter activity of the human ryudocan gene. J Biochem. 1996;119:979–84.PubMedCrossRef
8.
Zurück zum Zitat Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.PubMedCrossRef Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.PubMedCrossRef
9.
Zurück zum Zitat Beck CR, Collier P, Macfarlane C, Malig M, Kidd JM, Eichler EE, et al. LINE-1 retrotransposition activity in human genomes. Cell. 2010;141:1159–70.PubMedCentralPubMedCrossRef Beck CR, Collier P, Macfarlane C, Malig M, Kidd JM, Eichler EE, et al. LINE-1 retrotransposition activity in human genomes. Cell. 2010;141:1159–70.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Raiz J, Damert A, Chira S, Held U, Klawitter S, Hamdorf M, et al. The non-autonomous retrotransposon SVA is trans-mobilized by the human LINE-1 protein machinery. Nucleic Acids Res. 2012;40:1666–83.PubMedCentralPubMedCrossRef Raiz J, Damert A, Chira S, Held U, Klawitter S, Hamdorf M, et al. The non-autonomous retrotransposon SVA is trans-mobilized by the human LINE-1 protein machinery. Nucleic Acids Res. 2012;40:1666–83.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Callinan PA, Batzer MA. Retrotransposable elements and human disease. Genome Dyn. 2006;1:104–15.PubMedCrossRef Callinan PA, Batzer MA. Retrotransposable elements and human disease. Genome Dyn. 2006;1:104–15.PubMedCrossRef
14.
Zurück zum Zitat Taniguchi-Ikeda M, Kobayashi K, Kanagawa M, Yu CC, Mori K, Oda T, et al. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature. 2011;478:127–31.PubMedCentralPubMedCrossRef Taniguchi-Ikeda M, Kobayashi K, Kanagawa M, Yu CC, Mori K, Oda T, et al. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature. 2011;478:127–31.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Conley ME, Partain JD, Norland SM, Shurtleff SA, Kazazian HH. Two independent retrotransposon insertions at the same site within the coding region of BTK. Hum Mutat. 2005;25:324–5.PubMedCrossRef Conley ME, Partain JD, Norland SM, Shurtleff SA, Kazazian HH. Two independent retrotransposon insertions at the same site within the coding region of BTK. Hum Mutat. 2005;25:324–5.PubMedCrossRef
16.
Zurück zum Zitat Wilund KR, Yi M, Campagna F, Arca M, Zuliani G, Fellin R, et al. Molecular mechanisms of autosomal recessive hypercholesterolemia. Hum Mol Genet. 2002;11:3019–30.PubMedCrossRef Wilund KR, Yi M, Campagna F, Arca M, Zuliani G, Fellin R, et al. Molecular mechanisms of autosomal recessive hypercholesterolemia. Hum Mol Genet. 2002;11:3019–30.PubMedCrossRef
17.
Zurück zum Zitat Makino S, Kaji R, Ando S, Tomizawa M, Yasuno K, Goto S, et al. Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum Genet. 2007;80:393–406.PubMedCentralPubMedCrossRef Makino S, Kaji R, Ando S, Tomizawa M, Yasuno K, Goto S, et al. Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum Genet. 2007;80:393–406.PubMedCentralPubMedCrossRef
18.
Metadaten
Titel
SVA retrotransposition in exon 6 of the coagulation factor IX gene causing severe hemophilia B
verfasst von
Yuki Nakamura
Moe Murata
Yuki Takagi
Toshihiro Kozuka
Yukiko Nakata
Ryo Hasebe
Akira Takagi
Jun-ichi Kitazawa
Midori Shima
Tetsuhito Kojima
Publikationsdatum
01.07.2015
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 1/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1765-5

Weitere Artikel der Ausgabe 1/2015

International Journal of Hematology 1/2015 Zur Ausgabe

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.